Global Fetal And Neonatal Monitoring Devices Market

The magnetic resource imaging devices and equipment market consists of sales of magnetic resource imaging systems devices and equipment and related services. Magnetic resonance imaging (MRI) systems are imaging machines used to form pictures of inflammation or infection in an organ, degenerative diseases, strokes, musculoskeletal disorders, tumors, and other irregularities that exist in tissue or organs in a body. MRI systems use a fixed or static magnetic field and radio frequency signals to visualize anatomy, tissue characteristics, vascular flow, chemical composition of tissues, and perfusion and diffusion of tissues.

The global magnetic resonance imaging devices and equipment market is expected to decline from $8.1 billion in 2019 to $6.6 billion in 2020 at a compound annual growth rate (CAGR) of -18.8%. The decline is mainly due to the COVID-19 outbreak and the measures to contain it. The governments across the countries prioritized covid-19 screening and imaging is not routinely used to screen for COVID-19. Also, most of the factories manufacturing diagnostic imaging equipment such as X-ray systems, ultrasound systems, computed tomography (CT) scanners, and MRI systems and/or their components, are currently shutdown inorder to keep the staff safe and contain the spread. The market is then expected to recover and grow at a CAGR of 6.2% from 2021 and reach $10.2 billion in 2023.

In 2018, North America was the largest region in the magnetic resonance imaging devices and equipment market. This region is expected to remain the largest during the next five years. The magnetic resonance imaging devices and equipment market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

Changes in the lifestyle, technological advancement and increase in number of chronic diseases are increasing the demand for the diagnostics, driving the growth of MRI systems market. Magnetic resonance imaging (MRI) systems are used to produce three dimensional detailed anatomical images of the human body facilitating diagnosis, disease detection and treatment monitoring. The rising health concerns are increasing the demand for medical imaging technologies in healthcare centers for diagnosis. For instance, in India, 150,000 health and wellness centers with a budget of $ 1.8 billion enable the healthcare system more accessible. Increasing health consciousness and importance to health insurance is also causing significant growth in the market. For instance, in the USA, the number of uninsured dropped from 48.6 million in 2010 to 29.3 million in 2017 indicating an increase in the health concerns of the people.

Strict approvals and regulations by government bodies such as US Food and Drug Administration (FDA) is hampering the growth of magnetic resonance imaging systems, devices and equipment market. MRI systems manufacturers are required to comply several regulations in the form of device quality check, labeling, premarket approval, device investigation and reporting, apart from the regular registration process. Due to these stringent regulations, many manufacturers prefer to outsource the manufacturing to other countries where no such regulations are imposed. For instance, in July 2017, the European Medicines Agency (EMA), restricted the use of some linear gadolinium agents used in MRI body scans and to suspend the authorizations of others, as the gadolinium deposits are found in the brain after MRI scans. EMA has recommended these restrictions and suspensions in order to prevent any risks that could potentially be associated with gadolinium brain deposition.

Companies in the magnetic resonance imaging devices and equipment market are increasingly investing in advanced MRI imaging technologies to enhance their diagnosis and to reduce orders for rescans. The advanced MRI systems such as Multi contract MRI scanners, silent MRI Scanning technologies and others allow radiologists to modify patient`s image contrast after scanning, which is not possible with conventional imaging systems. For instance, in October 2017, the FDA cleared the first 7T MRI system, The Magnetom Terra from Siemens Healthineers, to strengthen the static magnetic field in the USA. Companies in the industry are collaborating to enhance technological advancements in the MRI systems and devices market. In September 2016, GE Healthcare collaborated with SyntheticMR AB to launch MAGiC (MAGnetic resonance image Compilation) software, the industry’s multi-contrast MRI system.

The EU agencies and US-FDA require 3 to 7 years along with all parts of the registration dossier to be submitted to approve the medical devices. The US-FDA assess each technical section for 6 months which may increase to another 6 months cycle if questions/concerns are raised. However, the technical sections’ assessment is done simultaneously and therefore the manufacturers should identify the time taking processes and plan the work accordingly and plan estimated date of approval. Also, the license validity and renewal of the application in EU region takes a toll on the manufacturer and adds to the existing regulatory burden. Therefore, the manufacturers of MRI systems, devices and equipment should plan well, communicate effectively in order to minimize the costs and reduce timelines.

The cardiovascular monitoring and diagnostic devices and equipment market consists of sales of cardiovascular monitoring and diagnostic devices and equipment and related services. The main product types of cardiovascular monitoring and diagnostic devices and equipment are cardiopulmonary stress testing systems, ECG data management systems, ECG monitoring equipment, ECG stress testing systems, event monitoring systems, and Holter monitoring systems. ECG monitoring equipment is an electronic device that is used to record the electrical activity of the heart. The various types involved are heart disease and coronary heart disease. The various end-users involved are hospitals/physician clinics (continuous glucose monitors), home/emergency, and research and development (clinical trials, universities, CRO). The global cardiovascular monitoring and diagnostic devices and equipment market size is expected to grow from $2.83 billion in 2021 to $3.12 billion in 2022 at a compound annual growth rate (CAGR) of 10.2%. The global cardiovascular monitoring and diagnostic devices market size is expected to grow to $4.34 billion in 2026 at a CAGR of 8.6%. The cardiovascular monitoring and diagnostic devices and equipment market is being driven by an increasing number of people suffering from obesity and diabetes. Risk factors including high blood pressure and high cholesterol are associated with obesity and diabetes leads to cardiovascular diseases. For instance, as per a study conducted by the American Heart Association (AMA), by 2030, 22.2 million CVD is expected to grow. According to another study conducted by AMA in the U.S., 26 million people have been diagnosed with diabetes, and above 9 million further, have the condition but it hasn't yet been diagnosed. The cardiovascular monitoring and diagnostic devices and equipment market is being restrained by the FDA's regulatory control over these devices based on the risks associated with this equipment. Cardiovascular monitoring and diagnostic devices fall into the class II category as per the FDA, which includes devices with moderate to high risk associated with usage. The Class II devices are specially controlled with performance standards which provide the manufacturers with performance specifications, postmarket surveillance which monitors the safety of the device after being released in the market, and also other standards like patient registries and special labeling requirements. For instance, Angel medical systems’ implantable cardiac monitor was unanimously rejected by a panel of FDA experts due to unmet performance specifications. ICMs continuously monitor the electrocardiogram (ECG) of the patient to conduct a real-time examination of the heart rhythm, for up to 36 months. ICMs are mostly used in the analysis of transitory symptoms which have an arrhythmic origin, such as unexplained palpitations. For example, in July 2020, Medtronic received U.S. Food and Drug Administration (FDA) clearance and European CE label approval for its Linq II insertable cardiac monitor (ICM) by remote programming, allowing clinicians to optimize device settings without the requirement for patients to return to the hospital. The US FDA has classified cardiovascular monitoring and diagnostic devices into the Class II category, as they have a moderate to high risk associated with usage. Class II devices are bounded by device-specific regulations which include performance standards, premarket data requirements, postmarket surveillance, and labeling requirements associated with device usage. For instance, the labeling should consist of contraindications, adverse reactions, precautions, warnings, and other instructions before the device is released into the market. Major players in the cardiovascular monitoring and diagnostic devices and equipment market are Medtronic PLC, Boston Scientific Corporation, GE Healthcare, Johnson & Johnson, Philips Healthcare, Siemens Healthcare, St. Jude MedicalInc, Nihon Kohden Corporation, FUKUDA DENSHI Co. Ltd, and Sorin Group. North America was the largest region in the cardiovascular monitoring and diagnostic devices and equipment market in 2021. Western Europe was the second-largest region in the global cardiovascular monitoring and diagnostic devices and equipment market. The regions covered in the cardiovascular monitoring market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cardiovascular monitoring and diagnostic devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The global cardiovascular monitoring and diagnostic devices and equipment market is segmented - 1) By Product Type: Cardiopulmonary Stress Testing Systems, ECG Data Management Systems, ECG Monitoring Equipment, ECG Stress Testing Systems, Event Monitoring Systems, Holter Monitoring Systems 2) By End-Use: Hospitals/Physician Clinic (Continuous Glucose Monitors), Home/Emergency, Research and Development (Clinical Trials, Universities, CRO) 3) By Type: Heart Disease, Coronary Heart Disease

The patient monitoring devices market consists of sales of patient monitoring devices and related services by entities (organizations, sole traders, and partnerships) that produce patient monitoring devices used in monitoring vital health parameters. The main types of patient monitoring devices market are fetal and neonatal monitoring devices, weight monitoring and body temperature monitoring devices and equipment, vital parameter monitoring devices and equipment, and remote patient monitoring devices and equipment. Fetal and neonatal monitoring devices measure the heart rate and rhythm of the baby (fetus). This lets the healthcare providers see how the baby is doing. The type of expenditure is public and private. The products used are instruments/equipment and disposables. The end-users are hospitals and clinics, diagnostic laboratories, and others. The global patient monitoring devices market size is expected to grow from $21.1 billion in 2021 to $23.55 billion in 2022 at a compound annual growth rate (CAGR) of 11.6%. The global patient monitoring market size is expected to grow to $35 billion in 2026 at a CAGR of 10.4%. The demand for monitoring devices is likely to increase due to the shortage of professionals in the healthcare services industry. According to a report by Mercer, the US requires 2.3 million new health care workers by 2025, this includes nurses, physicians, lab technicians, and various other healthcare personnel. This shortage is likely to drive the demand for monitoring systems as these devices allow medical professionals to track multiple patients remotely. This is expected to drive the market for patient monitoring devices in the forecast period. Awareness of diseases is low in many countries across the globe and this affected the demand for patient monitoring devices in the historic period. For instance, a study conducted by the Indian Council of Medical Research (ICMR) on 213 million people found that only 43.2% are aware of the chronic disease diabetes. This lack of disease awareness limited the diagnosis and treatment pool, thereby restricting market growth for patient monitoring devices. Patient monitoring device manufacturers are offering customized MPMs to cater to the growing patient pool. MPMs monitor different health parameters corresponding to patients’ health conditions. For instance, Infinium Medical’s Omni series monitors are preconfigured with ECG, oxygen saturation, non-invasive blood pressure, and temperature trackers. More advanced health measures such as invasive blood pressure, cardiac output, and anesthetic agent measurement can be added to this device when needed. Custom MPM is predominantly beneficial for tracking the health status of critically ill patients. Major companies in the patient monitoring devices market include General Electric Company, Koninklijke Philips N.V., Draegerwerk AG, Cardinal Health, Inc., Masimo, Stryker Corporation, Medtronic Inc., Edwards Lifesciences, Flex Ltd, and Nihon Kohden Corporation. Asia Pacific was the largest region in the global patient monitoring devices market in 2021. North America was the second-largest region in the global patient monitoring device market. The regions covered in the global patient monitoring market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the patient monitoring devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The global patient monitoring devices market is segmented - 1) By Type: Fetal and Neonatal Monitoring Devices, Weight Monitoring and Body Temperature Monitoring Devices and Equipment, Vital Parameter Monitoring Devices and Equipment, Remote Patient Monitoring Devices and Equipment 2) By End-User: Hospitals and Clinics, Diagnostic Laboratories, Others 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables Subsegments Covered: Fetal Monitoring Devices, Neonatal Monitoring Devices, Temperature Monitoring Devices, Weight Monitoring Devices, Cardiac Monitoring Devices, Neuromonitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Multiparameter Monitoring Devices, Cardiac Monitors, Respiratory Monitors, Hematological Monitors, Vital Parameter Monitors, Others

The anesthesia disposables market consists of sales of anesthesia disposables and related services. The anesthesia disposables are easy to use and portable devices. To a large extent, they have replaced the reusable ones and are largely used to the whole body or a targeted part of the body during tests and surgical operations so that the patient does not experience the pain and other sensations. The main products of anesthesia disposables are anesthesia breathing circuits, endotracheal tubes, anesthesia gas masks, and laryngeal mask airway. Laryngeal mask airways (LMA) are supraglottic devices that are used as a temporary method to maintain an open airway during the administration of anesthesia or as an immediate life-saving measure in a patient with a difficult or failed airway. The patient groups are neonatal, adult, and pediatric. The various end-users are hospitals, clinics, home care settings, and other end users. The global anesthesia disposables market size is expected to grow from $0.92 billion in 2021 to $1 billion in 2022 at a compound annual growth rate (CAGR) of 8.4%. The global anesthesia disposables market size is expected to grow to $1.3 billion in 2026 at a CAGR of 7.0%. The increase in the aging population leads to increased surgeries driving the anesthesia disposable market. Increasing life expectancies paired with age-related comorbidities have resulted in the growth of the elderly population who undergo surgeries. The prevalence of cardiovascular disease, arthritis, thyroid disease, and emphysema is steadily increasing, which is proportionally increasing the number of surgeries coupled with the growing prevalence of diseases. These diseases are found mainly in elderly people, which is increasing the consumption of anesthesia disposables as they are widely used in surgical procedures and are driving the market in the forecast period. Lack of trained anesthesiologists is restraining the market. Anesthetist plays a very vital role in patient's care during and posts any surgery or operation. They acquire the ability to offer a premium level of care to their patients. As with the increase in the number of patients especially for surgery and operations across the globe, the demand for skilled and trained anesthetists also increases. To meet rising patient demand for anesthesia services, countries are facing a critical shortage of skilled and trained anesthetists. For example, the Centre for Workforce Intelligence, a unit of UK NHS staffing agency Health Education England stated that according to their study, the demand for anesthetic services would grow by 25% by 2033, and would require the number of anesthetists to grow by 300 a year. As reported in a study conducted by the American Association of Medical Colleges (AAMC), a shortfall of 33,800 to 72,700 physicians across the specialties is expected by 2030. Thus there is a significant gap in the requirement of trained anesthesiologists across the country which is likely to hinder the growth of the anesthesia disposables market. The demand for cuffed endotracheal tubes (ETTs) in pediatrics is growing as compared to uncuffed ETTs. During pediatric anesthesia, general endotracheal intubation is commonly performed for airway management and positive pressure ventilation. Traditionally, uncuffed endotracheal tubes are recommended for children up to eight years old. But the major disadvantages of the uncuffed ETTs such as an increase in air leakage around the tube, make it difficult to ensure that the child is breathing adequate amounts of oxygen. In addition, the measurement of tidal volume is also compromised. Uncuffed ETTs also allow waste anesthetic gases to escape, contributing significantly to operating room contamination and rendering the anesthetic procedure more expensive. Therefore, the trend is towards increasing the usage of cuffed ETTs for pediatric procedures. According to the American Association of Nurse Anesthetists, facilities should select disposables registered with the U.S. Environmental Protection Agency (EPA) and follow manufacturer recommendations regarding use, exposure time, and disposal. Also, they should discard disposable single-use devices in a biohazardous bag/container (e.g., breathing circuits, airway devices, orogastric tubes) immediately after use. Major players in the anesthesia disposables market are Ambu A/S, Medline Industries Inc, Smiths Medical, Teleflex Inc, Vyaire Medical Inc, Armstrong Medical Ltd, Hamilton Medical AG, Intersurgical Ltd, Medtronic Plc, and Mercury Medical. Asia Pacific was the largest region in the anesthesia disposables market in 2021. Western Europe was the second-largest region in the global anesthesia disposables market. The regions covered in the global anesthesia disposables market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the anesthesia disposables market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The global anesthesia disposables market is segmented - 1) By Product: Anesthesia Breathing Circuits, Endotracheal Tubes, Anesthesia Gas Masks, Laryngeal Mask Airway 2) By End-User: Hospitals, Clinics, Home Care Settings, Others 3) By Patient Group: Neonatal, Adult, Pediatric

The temperature management market consists of sales of products or devices used to control and maintain specific body temperature through external warming or cooling for a specific duration. The temperature management devices are used in operation theatres during surgeries, ICU, blood warming, and in other chronic conditions such as cardiac ailments, neurological disorders, and cancer. The temperature management market covered in this report is segmented by product into patient warming devices and patient cooling devices. The patient warming devices are used to maintain specific body temperature through external warming. It is also segmented by application into surgery, cardiology, pediatrics, neurology, orthopedic surgery, others and by end-use into the operating room, neonatal ICU, emergency room, ICUs, and others. The global temperature management market size is expected to grow from $2.65 billion in 2021 to $2.75 billion in 2022 at a compound annual growth rate (CAGR) of 3.6%. The global temperature management market is expected to grow to $3.02 billion in 2026 at a CAGR of 2.4%. A rise in the prevalence of chronic diseases is expected to drive the temperature management market. For instance, in 2019, 1,762,450 new cancer cases and 606,880 cancer deaths are predicted to occur in the US. A decrease in temperature increases the inflammation or multiplying of cancer cells in patients. It also acts as a predictor of death for critically ill cancer patients. Hyperthermia, a type of treatment that uses a high temperature, is therefore used for treating cancer patients. Therefore, maintaining temperature for patients with chronic diseases helps in decreasing the infection and saving lives which in turn drives the temperature management market. The risk associated with the use of invasive temperature management devices is expected to hinder the temperature management devices. For instance, during the targeted temperature management post-cardiac arrest, the use of invasive temperature management devices is associated with certain risks like an injury at the area of placement, infection, and venous thrombosis. Similarly, surface cooling systems that use blankets or pads wrapped around the patient that circulates cold air or fluid include the rare risk of skin burns and irritation, as well as the risk of overshooting the target temperature in the induction phase. Such risk factors, therefore, are expected to impact the growth of the temperature management market. Wearables are evolving at a rapid pace and are expected to be the new trend in the temperature management system market. Heat due to power consumption causes both circuit malfunctions and low-temperature burns to users. Therefore, researchers are proposing thermal management methods using wearable devices with higher performance. A wearable device is a patch that controls the temperature of the patient’s body as per the wearer’s preference. For instance, the company Embr Labs has released a watch or bracelet called Embr Wave that makes the person feel warmer or cooler based on his preference, thereby acting as a personal thermostat. Major players in the temperature management market are 3M Company, Becton, Dickinson and Company, Draegerwerk AG & Co. KGaA, Smiths Medical, Stryker Corporation, The 37company (The Surgical Company), Zoll Medical Corporation (A Subsidiary of Asahi Kasei Corporation), C. R. Bard, Mennen Medical, and Medtronic (Covidien). The regions covered in the global temperature management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the temperature management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global temperature management market is segmented - 1) By Product: Patient Warming Devices, Patient Cooling Devices 2) By Application: Surgery, Cardiology, Pediatrics, Neurology, Orthopedic Surgery, Others 3) By End-Use: Operating Room, Neonatal ICU, Emergency Room, ICUs, Others

The ventilator devices market consists of sales of ventilators used in respiratory care for patients with acute or chronic respiratory disorders. The sales consist of revenues generated by establishments that are primarily engaged in the manufacturing of intensive care ventilators (critical care ventilators), neonatal care ventilators, and portable & transportable ventilators. The main types of ventilator devices are intensive care unit/critical care, transport/portable/ambulatory, and neonatal. Neonatal ventilator devices are kept in the healthcare settings for newborns and human infants during the first month after birth. The interface is invasive and non-invasive. The various end-users are hospitals and clinics, home care, ambulatory care centers, and others. The global ventilators market size is expected to grow from $3.73 billion in 2021 to $4.12 billion in 2022 at a compound annual growth rate (CAGR) of 10.4%. The global ventilator market size is then expected to grow to $6.08 billion in 2026 at a CAGR of 10.2%. There is an urgent and increased need for ventilators globally. This is because COVID-19 primarily manifests as an acute respiratory illness with pneumonia, and ventilators are the main supportive treatment for critically-ill patients. They assist or replace respiratory functions, pumping oxygen into the blood for vital organs. Therefore, the ventilators market is expected to grow significantly with the rapidly increasing cases of COVID-19 disease worldwide. The rising prevalence of respiratory diseases is driving the ventilators market. Chronic respiratory diseases such as asthma, bronchitis, pneumonia, and others resulting from different bacterial and viral infections and other causes will boost the demand for ventilators. The ventilators are respiratory devices that are used to support respiration in patients with chronic respiratory diseases. For instance, as of December 2020, 67.9 million COVID-19 cases were reported. Coronavirus infects the lungs causing pneumonia and other respiratory disorders affecting patients’ respiration. The emergence of such infectious diseases resulting in a pandemic is driving the ventilators market. The number of complications associated with the use of ventilators is expected to negatively affect the ventilators market. The ventilators cause complications including bronchopleural fistula, pneumothorax, and nosocomial pneumonia, and similar complications that result in a decrease in cardiac output, gastric problems and renal impairment, alkalosis. According to a report by Northwell Health COVID-19 Research Consortium in 2020, the death rate rose to 88% for those who received mechanical ventilation. The analysis of the report states that most of the patients could not survive after being placed on a mechanical ventilator. The companies in the ventilator market are increasingly expanding their ventilator production capabilities realizing the current demand due to the outbreak of the COVID-19 pandemic. COVID-19 is a respiratory disease caused by the coronavirus that infects the lungs causing pneumonia and other respiratory conditions. The patients affected with the virus suffer from severe pneumonia and lung dysfunction resulting in the need for ventilator support for respiration. For instance, in March 2020, Medtronic, a leading medical device manufacturer increased its ventilator production by 40%. Also, in March 2020, Philips targeted to increase its ventilator production capacity by 4-fold, to meet the rising demand. In July 2019, ResMed, a US-based medical device company acquired HB Healthcare for an undisclosed amount. This acquisition is to help millions of South Koreans living with sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. HB Healthcare is a South Korean home medical equipment provider. Major players in the ventilator devices market are Philips Healthcare, ResMed, Medtronic, Becton, Dickinson and Company, GE Healthcare, Hamilton Medical, Dräger, Getinge, Smiths Group, and Fisher & Paykel. Asia Pacific was the largest region in the ventilator devicess market. Western Europe was the second-largest region in the global ventilator devices market. The regions covered in the global ventilator devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the ventilator devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global ventilators market is segmented - 1) By Type: Intensive Care Unit/Critical Care, Transport/Portable/Ambulatory, Neonatal 2) By End-User: Hospitals and Clinics, Home care, Ambulatory Care Centers, Others 3) By Interface: Invasive, Non-Invasive

The fetal bovine serum market consists of sales of fetal bovine serum by entities (organizations, sole traders, and partnerships) that are engaged in manufacturing fetal bovine serum and related services. Fetal bovine serum refers to the liquid fraction of clotted blood from fetal calves, with reduced cells, fibrin, and clotting factors. It has high concentration of nutritional and macromolecular factors essential for cell growth and is a critical raw material for animal care, biotechnology, drug development, diagnostics, and other fields of research. The main types of fetal bovine serum are charcoal stripped, chromatographic, dialyzed fetal bovine serum, exosome depleted, stem cell, others. Charcoal stripped fetal bovine serum has activated carbon that helps lower levels of lipophilic compounds such as hormones, growth factors, and steroids and is used to conduct receptor or estrogen related studies. The fetal bovine serum is used in drug discovery, cell culture media, in vitro fertilization, human and animal vaccine production, diagnostics and others. Fetal bovine serum is used in various sectors including research and academic institutes, biotechnology and pharmaceutical industry, others. The global fetal bovine serum market size is expected to grow from $946.25 million in 2021 to $1,006.42 million in 2022 at a compound annual growth rate (CAGR) of 6.4%. The growth in the market mainly due to increase in R&D towards development of novel biopharmaceuticals. The fetal bovine serum market is expected to reach $1,275.93 million in 2026 at a CAGR of 6.1%. The increasing demand for biopharmaceuticals is expected to drive the growth of the fetal bovine serum market in the forecast period. A biopharmaceutical is a medicinal product that is derived from biological sources such as animals, humans, and microorganisms using biotechnology. Fetal bovine serum (FBS) is the most widely used substitute for animal cell culture media. Pharmaceutical firms, diagnostic laboratories, and researchers rely heavily on FBS for much of their cell culture requirements in biologics research. The global biologics market is expected to increase from $253.4 billion in 2020 to $420.5 billion by 2025. Therefore, the rising demand for biopharmaceuticals propels the growth of the fetal bovine serum market. Increasing collaborations between companies and research intuitions is a key trend gaining popularity in the fetal bovine serum market. Major companies are collaborating for increasing production capabilities, expanding market share and developing new products. For instance, in March 2021, Avant Meats, a Hong Kong-based cell-based marine protein startup, announced a strategic partnership with QuaCell Biotechnology, a biopharmaceutical company based in Guangdong, China, to reduce production costs and accelerate the commercialization of cultured meat. Avant claimed that by using its fetal bovine serum-free (FBS-free) cell culture media, it was able to cut production costs by 90%. The collaboration with QuaCell will further reduce costs by 75%. The collaboration is one of the earliest attempts to outsource production to a biopharmaceutical manufacturer. In December 2019, Sartorius, a German-based life science research and biopharmaceutical company acquired Biological Industries for $53.67 million. Through this acquisition, Sartorius expanded cell culture media and complementing the product portfolio for the users in the growing advanced therapies market in the majority portion of Biological Industries. Biological Industries is an Israel-based chemical and biotechnology company that provides fetal bovine serum for mammalian cell culture. Major players in the fetal bovine serum market are Sartorius AG, GE Healthcare, PAN- Biotech, Thermo Fisher Scientific Inc., Biowest, Bio-Techne, Rocky Mountain Biologicals Inc., Merck KGaA and TCS Biosciences Ltd. North America was the largest region in the fetal bovine serum market in 2021. Asia Pacific recorded the fastest growth during the forecast period. The regions covered in the FBS market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the fetal bovine serum market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global fetal bovine serum market is segmented - 1) By Product: Charcoal Stripped, Chromatographic, Dialyzed Fetal Bovine Serum, Exosome Depleted, Stem Cell, Others 2) By Application: Drug Discovery, Cell Culture Media, In Vitro Fertilization, Human and Animal Vaccine Production, Diagnostics, Others 3) By End-User: Research and Academic Institutes, Biotechnology and Pharmaceutical Industry, Others

The pediatric vaccines market consists of sales of pediatric vaccines and its related services used to provide immunity to infants and children for specific diseases. The pediatric vaccine is a preparation of killed microorganisms, living attenuated organisms, or living fully virulent organisms that are administered to stimulate the production of antibodies and provide immunity against one or several diseases among children. Pediatric vaccines are used in childhood immunization schedules to enhance a child’s immunity or prevent diseases such as diphtheria, tetanus, pertussis, influenza, Hepatitis B, polio, and many other infectious and non-infectious diseases. The main types of pediatric vaccines are monovalent and multivalent. A monovalent vaccine is made up of only one antigen strain. The technology used include live attenuated, inactivated, toxoid, conjugate and other technologies to provide immunity from infectious disease, allergy and cancer. The global pediatric vaccine market size is expected to grow from $31.44 billion in 2021 to $36.64 billion in 2022 at a compound annual growth rate (CAGR) of 16.5%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pediatric vaccine market is expected to reach $57.51 billion in 2026 at a CAGR of 11.9%. The rising prevalence of chronic diseases such as tuberculosis, diphtheria, and pneumonia in the age group of 15 years and below will contribute to the growth of the pediatric vaccines market. The risk of severe disease outcomes and complications of infectious diseases are increasing in children and adolescents with chronic conditions. According to the World Health Organization, chronic disease prevalence irose by 57% in the year 2020. The increased prevalence of chronic diseases among children rises the demand for immunization from chronic diseases, hence, driving the pediatric vaccines market’s growth. Vaccine refusal by parents for their children is a prevailing tradition in many countries. Among the reasons for withholding children for vaccination are lack of knowledge, religious and philosophical objections, exaggerated concerns regarding vaccine safety, and others. According to a nationwide survey found that over half (51%) of pediatric services in the United States have the policy to dismiss families that refuse childhood vaccines. 37% of pediatricians themselves said they often dismissed families for refusing vaccines, and 6% said they would dismiss a family for choosing to reach out to crucial early vaccines. Governments are imposing laws and organizing awareness programs to overcome parent’s and family’s resistance to the child’s vaccine, but are unable to impose any strict rules against parents’ refusal for children’s immunization, which may hinder the pediatric vaccines market’s growth. The demand for novel vaccines is steadily growing to deliver improved immunization against challenging infectious diseases (e.g. tuberculosis, HIV/ AIDS) and non-communicable chronic diseases such as cancer and neurodegenerative diseases. Novel approaches to vaccine development include structural immunogenic design, gene-based vaccine platforms, and effective adjuvant recombinant antigen formulations. To meet the increasing demand for novel vaccines, there is a continuous quest for pediatric vaccine manufacturers and developers for innovation of vaccine design and manufacturing technologies. For instance, in January 2020, Hilleman laboratories, global research, and development organization, has announced their plans to develop a novel vaccine against Group B Streptococcus, a major cause for neonatal infections in women, in the area of maternal and child health. Major players in the pediatric vaccines market are GlaxoSmithKline plc, Pfizer Inc., Sanofi S.A., Merck & Co., Inc., Indian Immunologicals Limited, AstraZeneca plc, CSL Limited, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Pvt. Ltd., Panacea Biotec Ltd., Zydus Cadila, BIO-MED, Squibb, Novartis, Abbott Laboratries, Eli Lillyand Company, F. Hoffmann- La Roche Ltd., Novo Nordisk A/S, VF Corporation, Sinovac Biotech Ltd., Bristol- Myers, Sun Pharmaceutical Industries Ltd, Sellas and Takeda Pharmaceutical Company Limited, Daiichi Sankyo, Bristol- Myers and Sinovac Biotec Ltd. North America was the largest region in the pediatric vaccines market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the pediatric vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pediatric vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global pediatric vaccine market is segmented - 1) By Vaccine Type: Monovalent, Multivalent 2) By Technology: Live Attenuated, Inactivated, Toxoid, Conjugate, Other Technologies 3) By Application: Infectious Disease, Allergy, Cancer